Cryptococcal meningitis (CM) has emerged as the most common life-threatening fungal meningitis worldwide. Current management involves a sequential, longitudinal regimen of antifungals; despite a significant improvement in survival compared with uniform mortality without treatment, this drug paradigm has not led to a consistent cure. Neurapheresis therapy, extracorporeal filtration of yeasts from cerebrospinal fluid (CSF) in infected hosts, is presented here as a novel, one-time therapy for CM. In vitro filtration of CSF through this platform yielded a 5-log reduction in concentration of the yeast and a 1-log reduction in its polysaccharide antigen over 24 hours. Additionally, an analogous closed-loop system achieved 97% clearance of yeasts from the subarachnoid space in a rabbit model over 4-6 hours. This is the first publication demonstrating the direct ability to rapidly clear, both in vitro and in vivo, the otherwise slowly removed fungal pathogen that directly contributes to the morbidity and mortality seen in CM.
Fungal meningitis is a debilitating condition involving subacute to chronic inflammation of the meninges in which microorganisms spill out from the bloodstream into the subarachnoid space or brain parenchyma. Invasion of all major human fungal pathogens can result in meningitis, including Candida, Aspergillus, Coccidioides, and, most commonly, Cryptococcus; due to neurological complications, cryptococcal meningitis (CM) is fatal if untreated [1] . Despite modern drug therapies, epidemiological estimates have cited a mortality rate from CM at 10%-30% in the United States and 50% or greater in Africa and Asia [2] [3] [4] . Given this prognosis, CM mandates early diagnosis and treatment with better fungicidal drugs or improved adjunctive therapeutic measures.
CM has emerged over the last half-century as the most common form of fungal meningitis in adults and is caused by inhalation of Cryptococcus neoformans, an encapsulated basidiomycete, or its sibling species Cryptococcus gattii. Contemporary estimates report >250 000 annual cases of CM and up to 150 000 deaths, down from 1 million cases and 600 000 deaths per year a decade ago [5, 6] . Yeasts can exacerbate their disease within the central nervous system (CNS) through shedding of a polysaccharide antigen (CrAg), as it can become lodged in arachnoid villi in concert with clumping yeasts and disrupt normal outflow of CSF from the subarachnoid space [7, 8] . Blockage of villi often results in acute elevated intracranial pressure (ICP) from the obstruction of CSF resorption, with CrAg and yeast burden roughly proportional to ICP increases [9] . This elevated ICP presents clinically as severe headache with possible visual or motor deficits, papilledema, or cerebellar/cerebral dysfunction; these complications can prove fatal [10] .
Pharmacological treatment of CM involves a combination of intravenous amphotericin B (AmB) and oral flucytosine for 2 weeks as primary induction therapy for most patients [11, 12] . This regimen is usually followed by daily administration of high-dose fluconazole for 8-10 weeks and low-dose oral maintenance therapy with fluconazole thereafter [13, 14] . Immediate and consistent administration of AmB with flucytosine is strongly associated with a fungicidal rate of approximately 0.4 log/day and an improved 70-day survival rate of the host [15] . Alternative drug regimens have been proposed, but are less effective at rapidly reducing the intrathecal fungal burden of CM.
Despite these pharmacological adjustments, successful treatment of CM remains difficult due to the lengthy drug regimen, measurable relapse rate, complications of increased ICP, and escalating healthcare costs [16, 17] . Penetration of AmB into the subarachnoid space is inherently poor due to both its large size and the selectivity of the blood-brain barrier; additionally, AmB's high nephrotoxicity and infusional side effect rate can be problematic [18] [19] [20] . Echinocandins are the most recently introduced class of drugs with potent antifungal effects and minimal nephrotoxicity, but have been shown to lack the ability to clinically treat C. neoformans [21] . Several clinical trials have demonstrated that rapid clearance of fungal burden within 2 weeks of infection is a primary determinant of survival, demonstrating the urgent need to effectively mitigate proliferation and accelerate elimination of yeasts from the CNS [15, [22] [23] [24] .
The Neurapheresis therapy system (Minnetronix, Inc) is an investigational closed-loop platform that simultaneously extracts contaminated CSF from the lumbar subarachnoid space via a custom dual-lumen catheter, passes it through a filtration system tailored to pathogen removal, and reintroduces filtered CSF into the midthoracic region through the same catheter. An automated pump sustains a desired circulation rate; the system is designed with the capability to pass the equivalent of the entire volume of human CSF through its filter approximately 20 times in a 24-hour period. Here we demonstrate the development and testing of a CSF filtration system as a potential novel adjunctive therapy for CM. The ability of mechanical filtration to directly remove the pathogen and secondary virulence factors also shows promise for remedy and reversal of other fungal meningitis subtypes.
METHODS

Culture of C. neoformans for Use In Vitro
H99, a clinical reference strain of C. neoformans, was grown for 24-48 hours at 30°C in yeast extract-peptone-dextrose (YPD) broth [25] . Yeast cells were washed with phosphate-buffered saline (PBS) and transferred to 10% Sabouraud dextrose broth buffered with 1M 3-(N-morpholino)propanesulfonic acid (MOPS) at 37°C for 24 hours to induce capsule growth. Cultures were diluted in artificial cerebrospinal fluid (aCSF; Cold Spring Harbor recipe) or Sabouraud/MOPS to clinically relevant concentrations (1 × 10 6 -1 × 10 8 cells/mL) for in vitro studies after being counted via trypan blue staining [26] .
Neurapheresis Filtration In Vitro
The Neurapheresis filtration system was assembled using tangential flow filters (TFFs) (Millipore Sigma) with pore sizes of 5 kDa or 100 kDa connected in a closed loop to the experimental ("stock") flask containing a high concentration of yeast (either 1 × 10 5 or 1 × 10 7 colony-forming units [CFU]/mL) in Sabouraud/MOPS via silicon tubing (Figure 1 ). TFFs were chosen for their ability to operate continuously at relatively high solid loads and their capacity to filter biological particles at the given diameter (C. neoformans is 5-10 µm) [27, 28] . TFFs were also deemed ideal for their effectiveness at removing cells without inducing lysis, as their design allows for C. neoformans to roll along rather than accumulate on the membrane. This cellular debris ("retentate") was collected in a waste reservoir at a rate of 0.2-0.25 mL/minute modulated by an adjustable back-pressure valve; the clean fluid ("permeate") passing through filtration cartridges was returned to the experimental flask to close the loop.
Prior to beginning filtration, the system was primed with 60 mL preservative-free aCSF to eliminate dead volume. One hundred fifty milliliters of the cell suspension was used to represent the total volume of CSF in humans [29, 30] . During filtration, the pump rate of the system was 2.5 mL/minute. The pump was stopped following each cycle (150 mL processed) of filtration for sampling; before resuming circulation, the stock was weighed and Sabouraud/MOPS was replenished to return the experimental flask to its original mass, thereby mimicking regeneration of CSF in vivo. Filtration was performed for approximately 24 hours.
Use of Animal Model
Three-to 5-kg pathogen-free New Zealand white rabbits (n = 13) were chosen for this study due to their affordability, size, familiarity as a robust cryptococcal animal model, and accessible subarachnoid space [27, 31] . To simulate CM, mature animals were sedated with ketamine (40 mg/kg) and xylazine (5 mg/kg), and inoculated intracisternally with 0.3 mL of aCSF containing 3 × 10 7 C. neoformans cells. Inoculations were preceded by daily hydrocortisone acetate (5 mg/kg) for immunosuppression. All veterinary procedures were preapproved by the Institutional Animal Care and Use Committee of Duke University.
Optimization of Leporine Neurapheresis Loop
To accommodate the low total volume of CSF (3-4 mL) and small subarachnoid space in the rabbit, the Neurapheresis system was modified for testing in vivo ( Figure 2 ). The total extracorporeal volume of this modified Neurapheresis system was approximately 2 mL. A 5-µm dead-end polyethersulfone membrane filter (Pall Corporation) was used instead of a TFF for its minimal priming volume requirements, low protein-binding capacity, and hydrophilicity. Additionally, its lack of waste line helped preserve small volumes of CSF in the animal model.
Optimization of dead-end filtration parameters was accomplished by passing 1 × 10 7 /mL C. neoformans yeasts through various pore sizes with a peristaltic pump (Watson-Marlow, Inc) and monitoring transmembrane pressure via a prefilter sensor. Postfiltration samples were collected to determine yeast clearance.
Validation of Leporine Neurapheresis Loop In Vitro
To verify that the altered Neurapheresis dead-end filtration system performed comparably to the TFF setup, 1 × 10 7 /mL C. neoformans cells were diluted in 5 mL aCSF and pumped through the loop with and without an attached dead-end filter. Samples of 0.3 mL were aspirated after every hour of filtration; a similar volume of aCSF was replaced through the lumbar injection port following sample collection. Transmembrane pressures were monitored via an attached sensor.
Surgical Procedures
Within 24-48 hours after infection with C. neoformans, animals were sedated intramuscularly with ketamine/xylazine and injected subcutaneously with dexamethasone (0.6 mg/kg) to minimize brain and spinal cord swelling. Ear arteries and veins were catheterized for fluid delivery and sample collection. The animals were positioned prone above a heated water blanket for temperature maintenance, intubated endotracheally, and connected to an isoflurane (2%-4%) ventilator and a noninvasive cardiac output monitor (Philips, Amsterdam, the Netherlands).
A stereotactic headstall was used to flex the head anteriorly for access to the cisterna magna. This apparatus, designed by our research team (patent pending), consists of a central cylindrical cradle to position the prone experimental animal, a pair of adjustable arms to anchor the head and allow proper flexion of the neck, and an adjustable chin rest (Supplementary Figure 1A-B) . As its components can rotate or slide freely, the device is easily scalable to a variety of experimental animals and procedures.
To visualize the subarachnoid space and implant the adapted Neurapheresis system in vivo, a lumbar laminectomy between L3 and L5 was performed on each rabbit using sterile microsurgical techniques. The dura mater was gently punctured with a 25G needle, and a 2Fr polyurethane catheter was advanced 3-5 cm intrathecally. The catheter was anchored via Dermabond (Ethicon, Inc) to prevent movement or CSF leakage. The same procedure was then performed at C1 and an identical catheter was inserted into the cisterna magna. Proper placement was confirmed by outflow of clear CSF. The leporine Neurapheresis loop was primed with 2 mL aCSF, then lumbar and cisternal catheters were connected to the presterilized filtration system to form a closed loop. During filtration, CSF was drawn from the cisterna magna and returned to the lumbar site, circulating at a rate of approximately 0.25 mL/minute. Serial CSF samples (~0.3 mL) were collected from the cisternal port after every complete cycle of filtration, and an equivalent volume of aCSF (Harvard Bioscience) was reinfused at the lumbar site. For the purposes of this study, a "cycle" was defined as the time taken for the system to process the total fluid volume between innate rabbit CSF (~1 mL/kg) and aCSF used for priming. Cycling was continued for 4-6 hours on average; the filtration system was then disconnected and final CSF samples were aspirated directly from the catheters. Experimental animals were then euthanized.
Yeast and Antigen Quantification
Samples from both in vitro and in vivo studies were vortexed, serially diluted in PBS, and spread via sterile glass beads onto Petri dishes prepared with YPD agar supplemented with chloramphenicol (100 µg/mL). Plates were incubated at 30°C for 72 hours and counted for CFUs. Yeast concentrations were calculated and log 10 -transformed via Microsoft Excel software.
Presence of CrAg was semiquantified via a lateral flow assay (LFA; IMMY). CSF samples were serially diluted in PBS, and CrAg concentration was estimated by fold changes to the assay's lower limit of detection.
Statistical Analysis
Statistically significant differences between groups were determined using a 2-sample t test at a confidence level of 95% (α = .05). All significance testing was performed within Microsoft Excel software.
RESULTS
Neurapheresis Filtration In Vitro Achieves a 5-Log Reduction of C. neoformans and a ≥1-Log Reduction of CrAg
Continuous filtration of C. neoformans (1 × 10 7 cells/mL) for 24 hours with 100-kDa TFFs resulted in a 5 ± 0.1-log (mean ± SD; 99.999%) reduction of yeasts in the stock flask ( Figure 3A) . These findings were corroborated by filtration of a lower yeast burden (1 × 10 6 cells/mL) with 5-kDa TFFs, as CFU counts were reduced below detectable limits within 24 hours (Supplementary Figure 2) .
Neurapheresis filtration with 100 kDa TFFs also accomplished a 1-log (90%) reduction in CrAg concentration within a flask of yeasts, as the LFA limit of detection was lowered 10-fold ( Figure 3B ). Comparable filtration through 5 kDa filters lowered the limit of detection 1000-fold, indicating a 3-log (99.9%) reduction in CrAg concentration.
Removal of C. neoformans via Dead-End Filtration Is Optimized With a
Pore Size of 5 µm When 1 × 10 7 yeasts/mL suspended in aCSF were pumped through polyethersulfone membrane dead-end filters of various pore sizes (0.2-70 µm), filters ≤5 µm in diameter lowered C. neoformans concentrations below detectable limits via CFU plating (P < .05). Larger-pored membranes were ineffective at removing yeasts, as concentrations of organism were relatively unchanged (~3 × 10 6 cells/mL) after filtration ( Figure 4) .
Maximum transmembrane pressure was also monitored during yeast filtration through dead-end filters. Five-micrometer filters performed with a peak transmembrane pressure of 13 ± 4.2 pounds per square inch (psi) (mean ± SD), significantly lower (P < .05) than filters with pores <5 µm, which had pressures exceeding 25 ± 1.5 psi (mean ± SD). Larger (≥10 µm) pores accomplished filtration of C. neoformans with no appreciable buildup in pressure. As 5-µm filters allowed for maximum filtration of yeasts with a lower peak transmembrane pressure than comparatively smaller ones, this size was selected for subsequent animal testing to ensure minimal risk of clogging or yeast lysis.
The Leporine Loop With 5-µm Filter Achieves Reduction of C. neoformans at a Rate Comparable to Tangential Flow Filtration
The leporine Neurapheresis loop, equipped with a 5-µm deadend filter, removed C. neoformans at a rate similar to 100-kDa TFFs: samples taken from the loop demonstrated a 3 ± 1.2-log (mean ± SD) reduction in yeasts over 5 hours of filtration in vitro, whereas control cultures remained viable over the course of study ( Figure 5 ). Prefilter pressure was found to not exceed 5.5 psi. Due to its competency in clearing C. neoformans over the anticipated length of an animal surgery, this adapted rabbit loop design was deemed acceptable for use in vivo.
The Leporine Neurapheresis Loop Performs a 1.6-Log Reduction of C. neoformans in the CSF of a CM Rabbit Model in 4-6 Hours
Neurapheresis filtration in New Zealand white (NZW) rabbits accomplished a 1.6 ± 0.5-log (mean ± SD; >97%) reduction of yeast cells in the intraloop circulating CSF within 6 hours compared with initial cisternal counts ( Figure 6 ). This clearance is far superior to the current standard antifungal treatment (intravenous AmB plus flucytosine), which is capable of, at most, a 0.6-log reduction in rabbits and a 0.4-log reduction in humans per day [15, 32] . CSF was also obtained directly from the cisternal catheter after filtration as a secondary measure of yeast clearance; on average, Neurapheresis therapy yielded a 0.6-log (>75%) reduction in fungal burden specific to the cisterna over 4-6 hours.
DISCUSSION
Implications for Treatment of CM
This study presents Neurapheresis filtration of infected CSF as a novel treatment for CM, with effects demonstrated both in vitro and in vivo. Tangential flow filtration of C. neoformans in an in vitro model accomplished a 5-log (99.999%) reduction in yeasts over the course of 24 hours, well above the clearance rate (0.4-log decrease in CFUs per day) typically achieved by the best combination antifungal treatment [13, 15] . A large (97%) decrease in yeast concentration was also found after just 4-6 hours of filtration in the NZW rabbit model of CM, supporting the viability of short-course Neurapheresis treatment in a living system. Similarly, concentrations of CrAg decreased substantially (≥90%) postfiltration, as the LFA limit of detection was lowered at least 10-fold. Removal of the polysaccharide CrAg responsible for occluding arachnoid villi, as well as rapid clearing of both single and clumping yeasts from the CSF, may reverse outflow obstruction in CM patients and alleviate resulting headaches and hydrocephaly. The ability of Neurapheresis to reduce C. neoformans and CrAg in an infected host demonstrates its potential to efficiently treat CSF adjunct to systemic antifungal therapy. Rapidity of clearing viable cryptococci from the subarachnoid space has consistently been shown to have considerable prognostic value, suggesting that patients burdened with a high organism load could especially benefit from Neurapheresis therapy [15, 24] . The Neurapheresis system is also expected to allow physicians to modulate the high ICP typical of CM patients more directly. The device presents a unique, 2-factor platform wherein flow can be partially diverted to drain excess CSF from the lumbar region. Alternatively, the waste rate (0.2-0.25 mL/minute) employed in experimental testing of the system can be lowered in clinical settings where fluid conservation is paramount. Shunting of extraneous fluid has been shown to alleviate altered mental status, papilledema, and cranial nerve palsies typical of CM patients, and may significantly decrease morbidity and mortality rates [33, 34] . Neurapheresis therapy may serve as a favorable alternative to other present drainage procedures by allowing direct and automated access to the intrathecal space while minimizing the need for repeated lumbar punctures and/or placement of shunts. The impact on cerebral edema as well as brain tissue antigen concentrations and viable yeast loads will require further investigations into long-term effects of the platform.
Justification of Adapted Leporine Filtration Loop
The closed-loop filtration system used in vivo contained several differences from the TFF design employed on the benchtop to accommodate the low volume of CSF in the animal model. Because attempts to aspirate fluid from the rabbit lumbar region were limited due to the small subarachnoid space, flow was directed head-to-tail for easier sampling. Additionally, a deadend filter was substituted into the modified loop because of its low dead space volume and lack of a waste line, minimizing the introduction of aCSF into the system during priming and the loss of CSF during filtration. This substitution was deemed acceptable, as negligible transmembrane pressure was observed during the use of dead-end filtration; furthermore, the ability of both methods to selectively remove the yeast and its antigen allowed for consistency in molecular content of the fluid returning to the animal.
Challenges of Adapted Leporine Filtration Loop
The aforementioned parameters were adapted to meet the unique needs of the rabbit model but involved several implications in testing. Although filtration capacity was shown to be comparable across both the dead-end filter and TFF systems in vitro, sampling from the experimental animal via needle ports during surgery proved to be technically challenging and less consistent. Cisternal CSF leakages and air infiltration were occasionally encountered during circulation, and may have led to some imprecise reporting of yeast concentrations. In cases where initial or final cisternal CSF samples were unobtainable, surgeries were excluded from our analysis. Also, the difficulty in keeping rabbits under general anesthesia for >6 hours limited the potential of this system to further reduce the CSF burden of yeasts in ways that would not pose issues in human hosts, who would be awake and monitored during the procedure. In general, however, animals showed a substantial drop in CSF yeast counts over the short filtration period used in this study.
Future Directions
Secondary morbidity and mortality from CM can often result from appearance of immune reconstitution inflammatory syndrome (IRIS), or excessive cytokine recruitment into CSF in response to infection [35] . Paradoxically, activation of these mediators can overcompensate for presence of the pathogen and overwhelm the immune system, leading to dangerous levels of inflammation or even IRIS within the CNS compartment [36] . Upcoming studies will explore the ability of the Neurapheresis interface to filter smaller mediators such as cytokines and chemokines to help control the neuroinflammatory response seen in CM. Neurapheresis therapy shows great promise in managing this cascade, as it combines mechanical circulation with tailored filter size for targeting a variety of cellular or subcellular targets (Supplementary Figure 3) . Given its utility, this platform is also an attractive choice for adjunctive treatment of other fungal meningitis groups, such as the medically incurable coccidioidal meningitis, that involve similar pathophysiology to CM. Furthermore, we have piloted Neurapheresis therapy in the treatment of other conditions such as bacterial meningitis and leptomeningeal disease, with promising initial results [37, 38] .
Future testing will also couple mechanical filtration of contaminated CSF through Neurapheresis with intrathecal infusion and circulation of drugs, including AmB. Ultimately, this platform is designed as an adjunctive therapy to the standard of care; in the future, it may ideally be optimized to facilitate targeted introduction of pharmacological agents into all regions along the neuraxis. Though some preliminary clinical trials have shown short-course intrathecal AmB to improve outcomes from CM, lumbar administration does not permit even distribution of the drug in the spinal column; moreover, repeated dosages often lead to hypertoxicity or intolerance [39, 40] . Neurapheresis therapy may improve upon the current standard of care by allowing for controlled, uniform flow of an antifungal or anticancer agent throughout the subarachnoid space and possibly into the remainder of the CNS as it filters yeasts. This combination of mechanical and pharmacological therapy is expected to clear yeasts at unprecedented speeds from the CNS while also having the ability to reduce systemic drug toxicity. Testing of the efficacy of AmB delivery through Neurapheresis in an in vitro spinal model and the rabbit model of CM is in progress.
A Neurapheresis device capable of performing extracorporeal filtration in human subjects is currently being tested through a first-in-human clinical trial (NCT02872636) that received US Food and Drug Administration Investigational Device Exemption approval to evaluate the performance of this catheter-based system in another patient population. A study testing the potential of Neurapheresis therapy to reduce fungal burden and CFUs in human patients with CM is currently being planned.
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